Likewise, combined treatment of TRAIL and HDACi vorinostat (suberanilohydroxamic acid, SAHA) in multiple myeloma (MM) (86), and sarcoma (87), and also HDACi valproic acid (VPA) in anaplastic thyroid carcinoma (ATC) (88), and head and neck cancer (HNC) (88) could defeat tumor cells resistance to TRAIL-induced apoptosis. This evidence concerns the gene TNFSF10 and head and neck cancer.